Literature DB >> 3264848

Lung function, smoking and survival in severe alpha 1-antitrypsin deficiency, PiZZ.

M C Wu1, S Eriksson.   

Abstract

Lung function, smoking, age and mortality data in 158 adult severe alpha 1-antitrypsin deficient, PiZZ individuals, followed from 1963 to 1982 were analyzed. Low initial FEV1 value was significantly associated with increased mortality (p less than 0.005). A 3 yr mortality rate of 40% was found in individuals whose initial FEV1 values were less than 30% of that predicted. In contrast, the corresponding 3-yr mortality among those whose initial FEV1 values were between 30 and 65% of that predicted was only 7%. Smokers were found to have significantly lower FEV1 levels (p = 0.008) and higher mortality (p less than 0.005) than non-smokers. The difference between current and ex-smokers in mortality and FEV1 level were not statistically significant (p = 0.9 and p greater than 0.25, respectively). Cross-sectional analysis of the initial FEV1 values indicated a significant decline (p less than 0.005) of FEV1 with increasing age. This decline was greater among smokers than non-smokers. Longitudinal analysis of FEV1 rates of decline in 80 cases with follow-up FEV1 measurements failed to detect any significant differences between smokers and non-smokers, but was performed late in the disease process. The application of these results to the planning of studies on replacement therapy, smoking intervention strategy and longitudinal follow-up is discussed.

Entities:  

Mesh:

Year:  1988        PMID: 3264848     DOI: 10.1016/0895-4356(88)90019-4

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  12 in total

Review 1.  Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy.

Authors:  R G Crystal
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

2.  Criteria for alpha 1-antitrypsin substitution.

Authors:  K Viskum; A Kok-Jensen
Journal:  Lung       Date:  1990       Impact factor: 2.584

3.  Decline in pulmonary function in patients with alpha 1-antitrypsin deficiency.

Authors:  T Evald; A Dirksen; S Keittelmann; K Viskum; A Kok-Jensen
Journal:  Lung       Date:  1990       Impact factor: 2.584

4.  Transmitting genetic risk information in families: attitudes about disclosing the identity of relatives.

Authors:  J T Wilcke; N Seersholm; A Kok-Jensen; A Dirksen
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

Review 5.  Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1997       Impact factor: 9.408

6.  Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha 1-antitrypsin deficiency (PiZZ).

Authors:  E Piitulainen; G Tornling; S Eriksson
Journal:  Thorax       Date:  1997-03       Impact factor: 9.139

Review 7.  Alpha-1-antitrypsin deficiency: current concepts.

Authors:  Alan T Mulgrew; Clifford C Taggart; N Gerry McElvaney
Journal:  Lung       Date:  2007-06-12       Impact factor: 2.584

8.  Purification and characterization by fast-atom-bombardment mass spectrometry of the polymorphonuclear-leucocyte-elastase-generated A alpha (1-21) fragment of fibrinogen from human blood after incubation with calcium ionophore A23187.

Authors:  R S Dewey; J M Liesch; H R Williams; E E Sugg; C A Dolan; P Davies; R A Mumford; G Albers-Schönberg
Journal:  Biochem J       Date:  1992-01-15       Impact factor: 3.857

Review 9.  Systematic review of the evidence relating FEV1 decline to giving up smoking.

Authors:  Peter N Lee; John S Fry
Journal:  BMC Med       Date:  2010-12-14       Impact factor: 8.775

10.  Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank.

Authors:  Adriano R Tonelli; Farshid Rouhani; Ning Li; Pam Schreck; Mark L Brantly
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.